Indaptus Therapeutics, Inc. (INDP) Dividend History

Indaptus Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology and infectious disease therapies. The company leverages its proprietary INDP-001 platform to create targeted treatments aimed at stimulating the immune system to fight cancer and infectious diseases. Headquartered in the United States, Indaptus aims to advance therapies that address unmet medical needs through cutting-edge research and development.

3 Columbus Circle, New York, NY, 10019
Phone: (646) 427-2727
Website: https://www.indaptusrx.com

Dividend History

Indaptus Therapeutics, Inc. currently does not pay dividends

Company News

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.

GlobeNewswire Inc.
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics presented positive interim safety data from a Phase 1 trial of its lead compound Decoy20, which showed an acceptable safety profile and signs of anti-tumor activity. The company plans to combine Decoy20 with a PD-1 inhibitor in a new cohort.

GlobeNewswire Inc.
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20

GlobeNewswire Inc.
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly

GlobeNewswire Inc.
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:27:09 UTC